Provenge sipuleucel-T regulatory update

CMS included several efficacy-related questions in its draft questions posted ahead of a Nov. 17 meeting to discuss Dendreon's Provenge sipuleucel-T prostate cancer therapy. CMS's Medicare Evidence De...